Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | PPARA | Q07869 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 1/20 | 0.65 |
| ▸ | PPARD | Q03181 | 1/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.60 |
| ▸ | ACR | P10323 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10584786 | 0.89 | PTGS1 (0.69) | PTGS1MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL30464902 | 0.89 | PTGS1 (0.76) | PTGS1MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL6861607 | 0.89 | PTGS1 (0.76) | PTGS1MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL16131104 | 0.87 | PTGS1 (0.74) | PTGS1MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL8743388 | 0.86 | PTGS1 (0.72) | PTGS1MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL14299273 | 0.86 | PTGS1 (0.72) | PTGS1MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL2556525 | 0.86 | PTGS1 (0.76) | PTGS1MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL891511 | 0.85 | PTGS1 (0.71) | PTGS1MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL6863539 | 0.85 | PTGS1 (0.71) | PTGS1MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL9309716 | 0.85 | PTGS1 (0.71) | PTGS1MEN1KMT2ACYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | PTGS1 3125/4885MEN1 4437/4885KMT2A 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.